Company / Revenue
United Therapeutics Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$3.2B
FY2025
5-year range
$1.7B / $3.2B
FY2021-FY2025
Trend
+10.6%
vs FY2024
Sector context
#25 of 155
Health Care
What the data says
United Therapeutics's revenue of $3.2B is higher than 84% of companies in the Health Care sector (FY2025). Revenue has increased for 6 consecutive years, from $1.4B in FY2019 to $3.2B in FY2025.
Based on SEC 10-K filings.
$3.2B in FY2025 with a 5-year CAGR of +16.5%. Top quartile in the Health Care sector.
Improved from $2.3B to $3.2B over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- +18.0%
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Sector benchmark
Top 16% in Health CareTop 16% of 155This company $3.2B Sector average $4.5B
▼
-28.8% below sector average
Key checks
Key Insights
- United Therapeutics's revenue has grown for 6 consecutive years.
- 5-year CAGR of +16.5%, indicating consistent growth.
- In FY2025, revenue increased 10.6% year-over-year.
- Ranks #25 out of 155 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 6.00 (safe zone, above 2.9 threshold)
- Strong profit margin: 40.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.2B | +10.6% |
| FY2024 | $2.9B | +23.6% |
| FY2023 | $2.3B | +20.2% |
| FY2022 | $1.9B | +14.9% |
| FY2021 | $1.7B | +13.6% |
| FY2020 | $1.5B | +2.4% |
| FY2019 | $1.4B | -11.0% |
| FY2018 | $1.6B | +11.1% |
| FY2017 | $1.5B | -8.3% |
| FY2016 | $1.6B | +9.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026